|
Age
|
47.2 ± 13.8
|
48.5 ± 12.2
|
0.46
|
|
Women (
n
,%)
|
117 (74%)
|
492 (78%)
|
0.25
|
|
First symptom (months)
|
6.6 ± 7.7
|
6.9 ± 8.5
|
0.72
|
|
DAS28
|
4.0 ± 1.0
|
5.4 ± 1.2
|
<0.0001
|
|
CRP level (mg/L)
|
17.2 ± 29.3
|
21.1 ± 33.1
|
0.0028
|
|
ESR
|
25.3 ± 22.4
|
30.6 ± 24.9
|
0.0014
|
|
Positive anti-CCP antibodies (
n
,%)
|
2 (1.26%)
|
313 (49.5%)
|
<0.0001
|
|
Positive RF (
n
,%)
|
5 (3.1%)
|
365 (57.75%)
|
<0.0001
|
|
Swollen-joint count
|
3.5 ± 2.4
|
8.2 ± 5.2
|
<0.0001
|
|
Tender-joint count
|
3.2 ± 2.6
|
9.9 ± 7.2
|
<0.0001
|
|
HAQ score
|
0.69 ± 0.58
|
1.05 ± 0.69
|
<0.0001
|
|
Diabetes mellitus (
n
,%)
|
7 (4.4%)
|
24 (3.8%)
|
0.73
|
|
HOMA-IR index
|
2.5 ± 2.6
|
2.8 ± 4.2
|
0.37
|
|
BMI
|
24.7 ± 4.6
|
25.2 ± 4.6
|
0.22
|
|
Steroid prescription at inclusion (
n
,%)
|
22 (13.8%)
|
84 (13.3%)
|
0.86
|
|
Radiographic damage at inclusion (
n
,%)
|
0 (0)
|
108 (17.1%)
|
<0.0001
|
|
Total SHS at inclusion
|
4.6 ± 6.8
|
6.14 ± 7.92
|
0.005
|
|
Erosive SHS
|
1.6 ± 3.13
|
3.09 ± 4.98
|
<0.0001
|
|
Narrowing SHS
|
2.97 ± 4.82
|
3.04 ± 4.36
|
0.77
|
|
Total SHS at 1 year
|
5.7 ± 9.5
|
7.7 ± 10.7
|
0.006
|
|
Erosive SHS
|
2.35 ± 5.05
|
4.48 ± 7.56
|
<0.0001
|
|
Narrowing SHS
|
3.36 ± 5.54
|
3.26 ± 4.78
|
0.9552
|
|
Total
∆
SHS between inclusion and 1 year
|
1.0 ± 3.8
|
1.6 ± 4.4
|
0.02
|
|
Erosive
∆
SHS between inclusion and 1 year
|
0.73 ± 2.7
|
1.37 ± 3.73
|
0.0025
|
|
Narrowing
∆
SHS between inclusion and 1 year
|
0.24 ± 1.22
|
0.26 ± 1.15
|
0.7294
|
|
Adiponectin level (μg/ml)
|
4.9 ± 3.4
|
5.0 ± 3.7
|
0.63
|
|
Leptin level (ng/ml)
|
14.6 ± 14.4
|
14.4 ± 13.7
|
0.74
|
|
Visfatin/NAMPT level (ng/ml)
|
4.1 ± 3.6
|
3.57 ± 3.1
|
0.47
|
